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Korean Patients with Superwarfarin Intoxication and Their 
Outcome
This observational study aimed at evaluating recent superwarfarin intoxication of Korean 
patients. Ten patients were diagnosed as or highly suspicious for superwarfarin 
intoxication. Case report forms described by attending hematologists of the patients were 
collected and analyzed. Bleeding symptoms were varied among the patients. Patients 
uniformly showed prolonged prothrombin time (PT) and activated thromboplastin time 
(aPTT) with decreased activity of vitamin K dependent coagulation factors. Positive serum 
brodifacoum test results in 4 of 5 requested patients contributed to confirmatory 
diagnosis. Psychiatric interview revealed an attempted ingestion in one patient. High dose 
vitamin K1 therapy promptly corrected prolonged PT and aPTT, but hasty discontinuation 
caused repeated bleeding diathesis in 6 patients. Route of intoxication was unknown or 
not definite among 8 of 10 patients. Three patients had a possibility of environmental 
exposure considering their occupations: there might be intoxication by transdermal 
absorption or inhalation. Therefore, high dose and prolonged use of vitamin K1 therapy is 
necessary for effective detoxification. Further detailed investigation on environmental 
exposure and efforts to improve availability of the blood level test in clinic are requested. 
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INTRODUCTION 
Attempted or accidental superwarfarin exposure has become 
an important public problem in Western countries (1), as intox-
ication can cause prolonged bleeding diathesis, and sometimes 
fatal results. Over 10,000 cases of superwarfarin intoxication were 
reported in 2008 to the Poison Control Centers Toxic Exposure 
Surveillance System in the United States (2). In Korea, only spo-
radic reports of superwarfarin intoxication exist without any 
systemic and detailed investigations to the issue (3-5). We con-
ducted an observational study of 10 cases of superwarfarin in-
toxication in Korea, most of them broke out within a year.
MATERIALS AND METHODS
Case report forms (CRF) for patients with superwarfarin intoxi-
cation were requested to 8 physicians from October 2009 to April 
2010 by electronic mails. Each of the physicians was an attend-
ing hematologist of the patients. A CRF contained filling up sec-
tion for basic information of a patient: age, sex, residence, occu-Hong J, et al.  •  Superwarfarin Intoxication in Korea
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pation, past history of disease, and medication history of anti-
coagulants or anti-platelet agents, etc. Manifestations of bleed-
ing were surveyed and initial laboratory data including pro-
thrombin time (PT) and activated partial thromboplastin time 
(aPTT) were collected. Results of plasma mixing test, activity of 
coagulation factors and serum brodifacoum level test were also 
recorded. Flow-sheet of treatment and change of laboratory 
data including PT and aPTT of each patient were gathered. The 
CRFs were analyzed by Hong J and Bang S-M and the results 
were reviewed by the other authors.
Ethics statement
This study was performed for the public good and had neither 
risk nor disadvantage for subjects. Therefore, the institutional 
Review Board of Seoul National Hospital Bundang Hospital 
permitted this study without acquisition of informed consent 
(Approval number: B-1007-106-105).
RESULTS
Patient characteristics, symptoms and diagnoses
Seven male patients and 3 female patients were reported in this 
survey. Their age ranged 37-83. Only one patient (patient 6) lived 
in a metropolitan city, and outbreaks were nationwide. Most of 
the cases occurred since 2009, except for a male patient who di-
agnosed in 2007 (4). Two of them have been previously pub-
lished as a case report (4, 5).
  Reported bleeding events were oral mucosal bleeding (7 pa-
tients), hematuria (4 patients), easy bruising (5 patients), hema-
toma formation (5 patients), and epistaxis (3 patients).
  Patients uniformly showed prolonged PT and aPTT with de-
creased activity of vitamin K dependent coagulation factors. 
Plasma mixing test and activities of coagulation factors were 
evaluated in all of the patients and the same result were showed: 
correction of PT and aPTT and decreased activities of factors II, 
VII, IX, and X. Serum brodifacoum test were requested in 5 of 
10 patients by physicians and 4 of them with a positive result 
were definitely diagnosed as superwarfarin intoxication. One 
patient (patient 2) repeatedly denied any contact with rodenti-
cides, but she confessed to trying to kill herself by taking roden-
ticides after an interview with a psychiatrist. One patient (pa-
tient 3) was initially witnessed ingestion of rodenticides by her 
neighbors so serum brodifacoum test was not performed. 
  Environmental exposure was a possible cause in 3 patients 
Table 1. Patients with superwarfarin intoxication in Korea
Patient ID    Age/sex Regions        Presentation
Studies  
(seconds)
(Possible) origin of  
superwarfarin exposure
Superwarfarin  
level test
Patient 1 Male/51 Pohang-si
Gyeongsangbuk-do
Oral mucosal bleeding
Hematuria
PT>110 
aPTT>240
Unknown (history of blackout after 
alcohol drinking)
Positive result
Patient 2 Female/37 Imsil-gun
Jeollabuk-do
Oral mucosal bleeding 
Epistaxis
Intramuscular 
Hematoma
PT 89.4 
aPTT 48.6
Intentionally for suicidal attempt 
(confessed after psychiatric interview)
Negative result
Patient 3 Female/80 Jeonju-si
Jeollabuk-do
Oral mucosal bleeding
Ecchymosis
Easy bruising
PT 52.3
aPTT 60.0
Intentionally for  
suicidal attempt
Not done (taking 
rodenticide was  
witnessed by others)
Patient 4 Male/43 Hanam-si
Gyeonggi-do
Hematoma collection  PT 117.9 
aPTT 87.5
Environ. Possibility; 
A horticulturist
Positive result 
Patient 5 (5) Male/52 Yangju-si
Gyeonggi-do
Epistaxis
Hematuria
Easy bruising
Conjunctival hemorrhage
Hemoperitoneum
PT 50.7 
aPTT 87.8
Unknown (ingested fluconazole for 
suicidal attempt and ingestion of other 
drugs cannot be ruled out)
Positive result
Patient 6 Male/45 Seoul Oral mucosal bleeding
Ecchymosis
Easy bruising
PT no clotting
aPTT 124.3
Unknown Not done
7-OH warfarin test was 
negative
Patient 7 Male/75 Masan-si
Gyeongsangnam-do
Oral mucosal bleeding
Gluteal hematoma
PT 96.4 
aPTT 96.4
Environ. Possibility; used rodenticide  
at his grain warehouse
Not done
Patient 8 Male/75 Goryeong-gun
Gyeongsangbuk-do
Epistaxis
Oral mucosal bleeding
Hematuria
Ecchymosis
Easy bruising
PT >100
aPTT 137.6
Unknown Not done
Patient 9 Female/83 Goryeong-gun
Gyeongsangbuk-do
Oral mucosal bleeding
Ecchymosis
Easy bruising
Hematoma collection
PT 36.6
aPTT 131
Unknown Not done
Patient 10 (4) Male/58 Chungcheongbuk-do Hematuria PT 165
aPTT 107
Environ. Possibility;  
A ragman
Positive result
PT, prothrombin time; aPTT, activated thromboplastin time; Environ., environmental.Hong J, et al.  •  Superwarfarin Intoxication in Korea
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(patients 4, 7, and 10) as they worked as a horticulturist, farmer, 
and ragman, respectively. Information for patient characteris-
tics, symptoms and diagnoses were summarized in Table 1. 
Treatment
Four patients (patient 1, 3, 4, and 6) failed to achieve sufficient 
correction of PT and aPTT initially so they had to increase dos-
es of vitamin K1 administration. Repeated prolongation of PT 
and aPTT due to hasty discontinuation was observed in 6 pa-
tients (patient 1, 2, 3, 4, 6, and 8). FFP was initially transfused to 
all of the patients, but repeated FFP transfusion with low doses 
of vitamin K1 failed to maintain normalization of PT and aPTT 
in 4 patients (patient 1, 3, 4, and 6).
  Durations of treatment were varied among the patients. Three 
patients (patient 1, 4, and 6) were completely discontinued vita-
min K1 treatment, and their duration of vitamin K1 administra-
tion was 7.3, 6.2, and 3.3 months, respectively. 
  All of the patients recovered or are on recovering from PT and 
aPTT prolongation without sequalae and there was no mortali-
ty. Only a patient (patient 5) received major surgical procedure, 
evacuation of hemoperitoneum. He confessed that he ingested 
excessive amount of fluconazole, an anti fungal agent, but repeat-
edly denied superwarfarin ingestion even positive result of brodi-
facoum level test was reported. It seems to be that he needed 
operation because of potentiated action of brodifacoum by drug 
interactions with the fluconazole.
  Information of treatment and state of recovery were summa-
rized in Table 2. 
DISCUSSION 
The discovery of warfarin dates back to outbreaks of cattle death 
in the northern United States and Canada in the 1920s (6). After 
isolation of the hemorrhagic compound in moldy silage which 
led to the death of the cattle, first generation anticoagulants in-
cluding warfarin were introduced. Warfarin is now widely used 
as a therapeutic anticoagulant, but its use as a rodenticide has 
declined because many rat populations have developed resis-
tance to it (6).  
  To overcome this resistance, second generation anticoagu-
lants, superwafarins were invented in the 1970s: brodifacoum 
and bromadiolone. They are highly lipid soluble and about 100 
times more potent than warfarin because of the phenyl groups 
replacing the terminal methyl group in the structure (7). In a 
Table 2. Treatment outcomes in our series and four others from the literature
Patients (Ref.)
Vitamin K1 treatment
Recovery
Initial dose, route and tapering schedule Duration (months)
Patient 1 10 mg IV q.d. intermittently→poor response→60 mg IV q.d. for a day→90 mg IV q.d. for 
a day→120 mg IV q.d. for 2 days→100 mg q.d. PO for 4 months→tapered for 3 months
  7.3  Recovered  
without sequalae
Patient 2 40 mg PO/day for a month→30 mg PO/day for 3 months→20 mg PO/day for a 
month→30 mg PO/day for 2 months→20 mg PO/day for a month→keep on therapy
>10 On recovering
Patient 3 30 mg PO/day for a week→poor response→60 mg PO/day for a month→40 mg PO/day 
for a month→30 mg PO/day for 3 months→15 mg PO/day for 3 months→10 mg PO/day 
for a month→keep on therapy
>7.7 On recovering
Patient 4 10 mg IV q.d. or 15 mg PO q.d. for 3.5 months→poor response→30 mg PO/day for 
12 days→poor response→60 mg PO/day for about 6 months→negative for follow up 
brodifacoum level→stop therapy 
  6.2 Recovered  
without sequalae
Patient 5 (5) 200 mg PO/day for 5 days with surgical drainage of hemoperitoneum 
→10 mg/day for 2 months→transfer to other hospital then F/U* loss
>3.6 On recovering
Patient 6 10 mg IV q.d. for 10 days→poor response→50 mg IV twice a week or 100 mg IM on the 
day IV was not performed for 5 weeks→50 mg IV once a week for a month→stop therapy
  3.3 Recovered  
without sequalae
Patient 7 10 mg IV bid for 5 days→15 mg IV bid for 3 weeks→F/U loss   1.0 Once recovered,  
then F/U loss
Patient 8 30 mg IV/day for 5 days→30 mg PO/day for 7 days→60 mg PO/day for 60 days
→keep on therapy
>2.2 On recovering
Patient 9 30 mg IV/day for 4 days→10 mg IV/day for 5 days→10 mg PO/day for 14 days
→keep on therapy
>0.8 On recovering
Patient 10 (4) 10 mg IV once for a week for 2 weeks→5 mg PO q.d. for 2 months and a week
→stop therapy
>2.6 Recovered  
without sequalae
Bruno et al. (19) 150 mg PO q.i.d. for 5 days 
→periodic tapering over the next 40 days
  1.5 Recovered
without sequalae
Pavlu et al. (14) 10 mg IV t.i.d. for 3 days→no response→100 mg PO q.d. for 7 days
→30 mg PO for 77 days→F/U loss
  2.9 Once recovered,  
then F/U loss
Zupancic-Salek et al. (17) 40 mg PO q.d. for 3 months→20 mg PO q.d. for 1 months 
→10 mg PO q.d. for 1 months→stop therapy
  5.0 Recovered
Hui et al. (11) 100 mg IV q.d. for 2 weeks→50 mg IV q.d. for 1 week 
→50 mg PO q.d. (Further treatment duration is not stated.)
Not stated Died 6 months  
after treatment
*F/U, follow up.Hong J, et al.  •  Superwarfarin Intoxication in Korea
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field test, 1-2 days feeding of brodifacoum was sufficient to 
achieve complete mortality in most of rodent species, com-
pared to 21 days of warfarin (8). The reported half life of brodi-
facoum in humans is much longer than that of warfarin (16-36 
days vs 17-37 hr) (9). 
  The most common clinical feature of superwarfarin intoxica-
tion is bleeding, and this can occur from any mucosal site or or-
gan. Various symptoms of bleeding were reported in the litera-
tures (1, 3, 4, 9-17) as in our study.
  Superwarfarin intoxication should be suspected in any pa-
tient who presents with a suspicious history and marked pro-
longation of both PT and aPTT without advanced liver disease 
or congenital coagulation factor deficiency. Mixing studies result 
in complete correction of PT and aPTT due to lack of inhibitors. 
Measuring the activity of vitamin K dependent coagulation fac-
tors (Factor II, VII, IX, and X), plasma vitamin K levels, or PIVKA-
II can be helpful in narrowing down the differential diagnosis. 
The definitive diagnosis is made by superwarfarin blood level 
testing with high performance liquid chromatography (HPLC) 
an accurate and effective way of determining the presence and 
concentration of superwarfarin. Recent advances in HPLC tech-
nology has made considerably accurate and rapid diagnosis 
possible (18), but such technology is not yet easily accessible in 
Korea. In our study, although one patient (patient 2) was highly 
suspicious for superwarfarin intoxication and she even confessed 
ingestion, a negative result was reported. Weitzel et al. (9) eval-
uated half-life of brodifacoum in 3 patients with superwarfarin 
intoxication by measuring serial serum brodifacoum concen-
trations. They reported the half-life ranged from 16 to 36 days in 
3 patients and serum brodifacoum had been no longer detect-
ed after 2 months from the time of initial diagnosis, although 
bleeding tendency continued more than 100 days. Considering 
of their result, serum brodifacoum level in the patient of our study 
might be decreased to undetectable range at the time of sample 
request, as superwarfarin level test had been requested about 
100 days after initial symptom presentation by her physician.
  Administration of vitamin K1 is the cornerstone of therapy   
in patients with superwarfarin intoxication. Oral vitamin K1 is 
preferred to intramuscular or intravenous injection, as it avoids 
hematoma formation and hypersensitivity reactions. An opti-
mal dose and duration of vitamin K1 therapy has yet to be estab-
lished (19). However, most previous studies support multiple, 
prolonged, and high dose vitamin K1 supplementation (1, 14-
16, 19). As the half-life of vitamin K1 is 6 hr (7), multiple divided 
doses of vitamin K1 has the advantage of maintaining therapeu-
tic effect. Prolonged use of high dose vitamin K1 is necessary as 
the half-life of superwarfarins is substantially long (9). Early ta-
pering or discontinuation will result in repeat prolongation of 
PT and aPTT even after normal levels have been achieved (12). 
This repeat prolongation due to hasty discontinuation was ob-
served in 6 of our patients (patient 1, 2, 3, 4, 6, and 8) and in pre-
vious reports (10, 14). A phased and prudent tapering of vita-
min K1 with regular follow up is thus mandatory (15). In a case 
series of 9 patients in Taiwan (16), treatment duration ranged 
from 72 to 185 days. Table 2 shows the doses and durations of 
vitamin K1 therapy performed in our study and several previ-
ous reports. In a situation of emergency due to bleeding, trans-
fusion of coagulation factors is effective, although the effect of 
this will be transient because of long half-life of superwarfarin. 
Urgent treatment with vitamin K1 and transfusion of coagula-
tion factors based on clinical suspicion alone is justified because 
most detailed laboratory tests require several days to weeks. 
  Identifying the source of exposure is sometimes challenging 
in patients who deny ingestion of superwarfarin. After stabiliza-
tion of symptoms, psychiatric interview should be recommend-
ed for patients in whom intentional administration is highly sus-
pected as patient 2 of this study. We were unable to definitively 
identify the route of intoxication in 8 of the patients in this study. 
Environmental exposure was a possible cause in 3 patients (pa-
tients 4, 7, and 10) considering their occupations. As these pa-
tients had no symptoms or history of mental illness, and taking 
into account the potency, lipid solubility and long-half life of su-
perwarfarin, we can cautiously consider transdermal absorption 
and inhalation as potential routes of their superwarfarin expo-
sure. Such possibilities were highlighted in a previous report on 
2 patients who worked in superwarfarin manufacture (3).
  The incidence of superwarfarin intoxication should be sur-
veyed nationwide in light of these recent cases. Supervision for 
rodenticide use and education of people who deal with roden-
ticides in their workplace are also necessary, along with further 
scientific research to achieve more accurate diagnosis and treat-
ment of superwarfarin intoxication.
  In conclusion, early suspicion with a prompt request of serum 
brodifacoum test and sufficient dose and duration of vitamin 
K1 therapy is necessary for effective treatment of superwarfarin 
intoxication. Further detailed investigation on the possibility 
and the actual condition of environmental exposure, and im-
proving availability of the blood level test is mandatory. 
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